product information
(+/-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxy phenoxy)propry]-1-piperazine acetamide
CAS number: 95635-55-5
Groups: All Chemicals
IUPAC Name: N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide

CAS Number: 95635-55-5

Chemical Formula: C24H33N3O4

Synonyms: 142387-99-3, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, 95635-55-5, BSPBio_002276, C24H33N3O4, CID56959, CVT-303, D05700, DB00243, KEG-1295, Latixa, Lopac0_001062, LS-187267, MLS002154149, N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide, N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]ethanamide, NCGC00095177-01, NCGC00095177-02, NCGC00095177-03, Ran4, RAN D, Ranexa, Ranexa (TN), ( -)-Ranolazine, (-)-Ranolazine, RANOLAZINE, Ranolazine 2HCl, Ranolazine dihydrochloride, Ranolazine [USAN], Ranolazine (USAN/INN), RS-43285, RS-43285-003, SMR000857382, SPECTRUM1505366

Product Info: Ranolazine is a potential anti-anginal agent that acts by shifting ATP production away from fatty acid oxidation in favor of glucose oxidation. Because more oxygen is needed to phosphorylate a given amount of ATP during fatty acid oxidation than during carbohydrate oxidation, the ranolazine-induced shift in substrate utilization reduces oxygen demand without decreasing the ability of the tissue to do work.In three placebo controlled studies in angina patients, an immediate release (IR) formulation of ranolazine increased treadmill exercise parameters without associated changes in rest or exercise heart rates or decreases in rest or exercise blood pressures. Statistically significant increases in exercise times were only observed, however, after doses of > 240 mg, when ranolazine plasma concentrations were near their peak. There was no evidence for anti-anginal efficacy 8 or 12 hours after any dose. These studies suggested potential for ranolazine as an anti-anginal drug but indicated that the immediate release formulation was impractical because of the short duration of its effect. They did, however, provide information concerning ranolazine plasma concentrations necessary for an anti-anginal effect. Based on these results, a sustained release (SR) formulation of ranolazine was developed. Another study has shown that subjects treated concomitantly with ranolazine and diltiazem allows the higher ranolazine plasma levels to occur. Both ranolazine SR and IR appear to be safe and well tolerated in short-term, solid blind, placebo controlled trials which have included over 1400 patients, most of whom had stable angina. (

In the current, pilot study, researchers found that a drug, ranolazine (brand name Ranexa, CV Therapeutics) shortens the QT interval by about 5 percent; just enough to reduce symptoms and risks associated with one form of LQTS (LQT3-deltaKPQ). It is one of three forms of the disease that together make up 90 percent of LQTS cases. Past studies have shown that patients with angina, severe chest pain caused by inadequate blood flow to the heart, are also more likely to experience arrhythmias. Researchers got a clue that ranolazine, approved in January 2006, might influence QTc during its angina clinical trials, where it was found to have electrophysiological side effects.

The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. (
Leave some information and we will contact you ASAP about the quotation of this product!
Company name:
Your name:
Your E-mail address:
Required quantity:
Repeat Anti-Bot code: security code


P&S Chemicals
Hendrik Ido Ambacht, The Netherlands.
Disclaimer | Contact Us | Show Products
© 2012 P&S Chemicals. All rights reserved.